Multiple Myeloma – Cell Therapies 15-Market Assessment and Sales Forecast to 2031

Powered by

Access in-depth insight and stay ahead of the market

Multiple Myeloma Cell Therapy Market Report Overview

The total market value for the 15M, which includes both cell therapies and established/traditional MM therapies was $25.7 billion in 2021. The following are some of the key highlights of the multiple myeloma cell therapy market:

  • The market growth will be attributed to the established CAR-T agents such as Abecma and Carvykt.
  • The success of CAR-Ts in MM has fueled R&D investment into this class of therapy, with more CAR-Ts in development than all other cell and gene therapy (cell therapy) classes combined.
  • In multiple myeloma, protein levels are routinely used to diagnose and monitor disease progression.
  • Leading MM players, such as Johnson & Johnson and Bristol Myers Squibb, are all looking to bolster their positions as market leaders by entering their cell therapies into trials for earlier-stage settings.

Multiple Myeloma Cell Therapy Market Outlook, 2021-2031 ($ Billion)

Multiple Myeloma Cell Therapy Market Outlook, 2021-2031 ($ Billion)

Buy the Full Report to Know More about the Multiple Myeloma Cell Therapy Market Forecast

Download a Free Report Sample

The MM cell therapy market research report offers a comprehensive insight into the market through 2032. The report provides an overview of the disease including epidemiology, symptoms, diagnosis, disease management, countries where the disease is prevalent, and leading players associated with the market.

Market Size (2021) $25.7 billion
Forecast Period 2021-2031
Key Regions ·       APAC

·       Europe

·       Middle East

·       North America

Leading Players ·       Johnson & Johnson

·       Teva Pharmaceutical Industries Ltd

·       F. Hoffmann-La Roche Ltd

·       Novartis AG

·       Bristol Myers Squibb Co

Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Multiple Myeloma Cell Therapy Market Dynamics

Patients may prefer more convenient therapies that do not require IV administration, which is one of the factors hampering the MM cell therapy market growth. However, the large pipeline of CAR-T agents in late-phase clinical trials is expected to gain approvals in later-line settings and capture significant market share due to high unmet need in these settings in the coming years.

Multiple Myeloma Cell Therapy Market Analysis by Treatment

  • The approval of CAR-T cell therapies such as Abecma and Carvykti has provided viable treatment options for patients requiring drugs in later-line settings.
  • The launch of Carvykti in China for use in 3L+ settings will address an unmet need. These marketed CAR-T cell therapies aim to move into earlier lines of therapy. Meanwhile, Abecma may address the needs of patients with high-risk cytogenetics as it is currently in a trial for later-line settings.

Buy the Full Report for More Insights into the Multiple Myeloma Cell Therapy Market Treatment

Download a Free Report Sample

Multiple Myeloma Cell Therapy Market Segmentation by Regions

North America had the highest sales in 15MM in the MM cell therapy market.

A few of the key regions in the market are APAC, Europe, Middle East, and North America.

Multiple Myeloma Cell Therapy Market Analysis by Regions, 2021 (%)

Multiple Myeloma Cell Therapy Market Analysis by Regions, 2021 (%)

Buy the Full Report for More Regional Insights into the Multiple Myeloma Cell Therapy Market

Download a Free Report Sample

Multiple Myeloma Cell Therapy Market - Competitive Landscape

The clinical pipeline for cell therapies in MM has candidates from many different companies, largely small-to-medium sized US- or China-based biotechs and large global pharma companies. Moreover, Carvykti was approved based on a Phase I/II trial, and the number of ongoing Phase I–III trials could indicate a myriad of approvals over the forecast period.

A few of the major players in the Multiple Myeloma Cell Therapy market are:

  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd
  • Hoffmann-La Roche Ltd
  • Novartis AG
  • Bristol Myers Squibb Co

Multiple Myeloma Cell Therapy Market Analysis by Companies

Multiple Myeloma Cell Therapy Market Analysis by Companies

Buy the Full Report to Know More about Companies in the Multiple Myeloma Cell Therapy Market

Download A Free Report Sample

Multiple Myeloma Cell Therapy Country Outlook (Value, $ Billion, 2021-2031)

  • APAC
  • Europe
  • Middle East
  • North America

Reasons to Buy

The report includes:

  • What is the target patient pool for cell and gene therapies in each cancer indication?
  • Which patient groups are more likely to receive these therapies?
  • What does the cell & gene therapy clinical-stage pipeline look like in each cancer indication?
  • What is the anticipated breakdown between autologous and allogeneic cell therapies?
  • When will cell & gene therapies launch in each market?
  • What is the total market value projected for the forecast end, in 2031?

Key Players

BMS
J&J
Nanjing IASO Biotherapeutics
Arcellx
CARsgen Therapeutics

Table of Contents

Table of Contents (PowerPoint Deck)

1. Preface

1.1. Contents

1.2. Report Scope

2. Executive Summary

3. Disease Overview

3.1. MM Etiology & Staging

3.2. Treatment Algorithm

4. Marketed & Pipeline Drugs Overview

4.1. Marketed Drugs Overview

4.2. Pipeline Analysis

4.3. Target Analysis and Clinical Benchmarks

5. Market Outlook

5.1. 10-Year Market Analysis with Drivers and Barriers

5.2. 10-Year Market Outlook – 15 Markets

6. Unmet Needs

7. Likelihood of Approval Analysis and Phase Transition Success Rate Analysis

8. Competitive Assessment

8.1. Competitive Analysis by Class of Therapy

9. Future Players

9.1. Future Players Based on Pipeline Strength

10. Appendix

10.1. Cell Therapies Forecast Methodology Overview

10.2. Pricing of Cell Therapies

10.3. Pipeline Launch Assumptions

10.4. Abbreviations

10.5. Methodology

10.6. About the Authors

11. Contact Us

Frequently asked questions

Currency USD
$9,995

Can be used by individual purchaser only

$29,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

We are confident about Multiple Myeloma – Cell Therapies 15-Market Assessment and Sales Forecast to 2031 report's unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Multiple Myeloma – Cell Therapies 15-Market Assessment and Sales Forecast to 2031 in real time.

  • Access a live Multiple Myeloma – Cell Therapies 15-Market Assessment and Sales Forecast to 2031 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.